SPRTN protease-cleaved MRE11 decreases DNA repair and radiosensitises cancer cells.
Acid Anhydride Hydrolases
/ genetics
Cell Cycle Proteins
/ genetics
Cell Line, Tumor
Cell Proliferation
/ radiation effects
DNA Damage
DNA Repair
DNA-Binding Proteins
/ genetics
G2 Phase Cell Cycle Checkpoints
/ radiation effects
HEK293 Cells
Humans
MRE11 Homologue Protein
/ genetics
Nuclear Proteins
/ genetics
Proteolysis
Radiation Tolerance
Substrate Specificity
Urinary Bladder Neoplasms
/ enzymology
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
08 02 2021
08 02 2021
Historique:
received:
05
06
2020
accepted:
11
01
2021
revised:
07
01
2021
entrez:
9
2
2021
pubmed:
10
2
2021
medline:
14
9
2021
Statut:
epublish
Résumé
The human MRE11/RAD50/NBS1 (MRN) complex plays a crucial role in sensing and repairing DNA DSB. MRE11 possesses dual 3'-5' exonuclease and endonuclease activity and forms the core of the multifunctional MRN complex. We previously identified a C-terminally truncated form of MRE11 (TR-MRE11) associated with post-translational MRE11 degradation. Here we identified SPRTN as the essential protease for the formation of TR-MRE11 and characterised the role of this MRE11 form in its DNA damage response (DDR). Using tandem mass spectrometry and site-directed mutagenesis, the SPRTN-dependent cleavage site for MRE11 was identified between 559 and 580 amino acids. Despite the intact interaction of TR-MRE11 with its constitutive core complex proteins RAD50 and NBS1, both nuclease activities of truncated MRE11 were dramatically reduced due to its deficient binding to DNA. Furthermore, lack of the MRE11 C-terminal decreased HR repair efficiency, very likely due to abolished recruitment of TR-MRE11 to the sites of DNA damage, which consequently led to increased cellular radiosensitivity. The presence of this DNA repair-defective TR-MRE11 could explain our previous finding that the high MRE11 protein expression by immunohistochemistry correlates with improved survival following radical radiotherapy in bladder cancer patients.
Identifiants
pubmed: 33558481
doi: 10.1038/s41419-021-03437-w
pii: 10.1038/s41419-021-03437-w
pmc: PMC7870818
doi:
Substances chimiques
Cell Cycle Proteins
0
DNA-Binding Proteins
0
MRE11 protein, human
0
NBN protein, human
0
Nuclear Proteins
0
SPRTN protein, human
0
MRE11 Homologue Protein
EC 3.1.-
Acid Anhydride Hydrolases
EC 3.6.-
RAD50 protein, human
EC 3.6.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
165Subventions
Organisme : Cancer Research UK
ID : C5255/A23755
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 211944/Z/18/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00001/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_EX_MR/K022830/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_12001/1
Pays : United Kingdom
Références
PLoS Genet. 2008 Jun 27;4(6):e1000110
pubmed: 18584027
Curr Biol. 2000 Jul 27-Aug 10;10(15):886-95
pubmed: 10959836
DNA Repair (Amst). 2004 Aug-Sep;3(8-9):953-7
pubmed: 15279781
FEBS Lett. 2010 Sep 10;584(17):3682-95
pubmed: 20655309
Mutat Res. 2001 Jun 2;477(1-2):131-53
pubmed: 11376695
G3 (Bethesda). 2013 Nov 06;3(11):1927-43
pubmed: 24062528
J Proteome Res. 2017 Mar 3;16(3):1288-1299
pubmed: 28164708
Cell. 2008 Oct 3;135(1):85-96
pubmed: 18854157
Cell. 2004 Sep 17;118(6):699-713
pubmed: 15369670
Oncogene. 2020 May;39(19):3952-3964
pubmed: 32203168
Nat Rev Mol Cell Biol. 2011 Feb;12(2):90-103
pubmed: 21252998
J Biol Chem. 2003 Nov 14;278(46):45171-81
pubmed: 12966088
Nat Struct Mol Biol. 2009 Aug;16(8):798-800
pubmed: 19654615
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7376-81
pubmed: 10377422
Cancer Res. 2010 Sep 15;70(18):7017-26
pubmed: 20843819
Int J Hyperthermia. 2004 Mar;20(2):157-62
pubmed: 15195510
Nat Rev Cancer. 2008 Dec;8(12):957-67
pubmed: 19005492
Mol Cell. 2016 Nov 17;64(4):704-719
pubmed: 27871366
Chromosoma. 2009 Dec;118(6):683-92
pubmed: 19707781
Mol Cell. 1998 Jun;1(7):969-79
pubmed: 9651580
Mol Cell. 2018 Aug 2;71(3):419-427
pubmed: 30057197
EMBO J. 2014 Dec 1;33(23):2847-59
pubmed: 25349191
Mol Cell Biol. 2008 May;28(9):3058-69
pubmed: 18285453
Genes Dev. 2005 Mar 15;19(6):671-6
pubmed: 15741314
Nat Rev Mol Cell Biol. 2002 May;3(5):317-27
pubmed: 11988766
Curr Protoc Chem Biol. 2009 Dec 1;1(1):1-15
pubmed: 23839960
Nat Struct Mol Biol. 2011 Apr;18(4):423-31
pubmed: 21441914
Bioinformatics. 2010 Mar 15;26(6):752-60
pubmed: 20130033
J Biol Chem. 2003 May 30;278(22):20303-12
pubmed: 12660252
BJU Int. 2012 Dec;110(11 Pt C):E1228-36
pubmed: 23046361
Science. 2002 May 3;296(5569):922-7
pubmed: 11934988
DNA Repair (Amst). 2010 Dec 10;9(12):1299-306
pubmed: 21035407
Mol Cell Biol. 2001 Jan;21(1):281-8
pubmed: 11113202
Nat Commun. 2019 Jul 17;10(1):3142
pubmed: 31316063
Curr Biol. 2001 Mar 20;11(6):R229-32
pubmed: 11301269
Cell Res. 2012 Feb;22(2):305-20
pubmed: 21826105
Cold Spring Harb Protoc. 2009 Feb;2009(2):pdb.prot5110
pubmed: 20147065
Curr Biol. 2001 Jan 23;11(2):105-9
pubmed: 11231126
Methods Enzymol. 2018;601:205-241
pubmed: 29523233
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Cell. 2007 Nov 30;131(5):887-900
pubmed: 18001824
Cancer Res. 2017 Jun 1;77(11):3027-3039
pubmed: 28363998
Cell Cycle. 2011 Jul 1;10(13):2218-32
pubmed: 21623170
Clin Cancer Res. 2014 Nov 1;20(21):5435-45
pubmed: 25224279
Cell. 1999 Dec 10;99(6):577-87
pubmed: 10612394
Sci Rep. 2017 Oct 3;7(1):12587
pubmed: 28974723
Breast Cancer Res. 2014 Jun 03;16(3):R58
pubmed: 24894818
Oncogene. 2018 Jan 25;37(4):427-438
pubmed: 28967905
Mol Cell. 2014 Jan 9;53(1):7-18
pubmed: 24316220
Nature. 2008 Oct 9;455(7214):770-4
pubmed: 18806779